MedTrace Logo

Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer

NCT02124681 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2017-06-06

No results posted yet for this study

Summary

Current options to treat insulin resistance in diabetes are fairly limited. For this reason, novel treatments would represent a major progress. The generic drug hydroxychloroquine (HCQ) has poorly understood effects on blood sugar metabolism. In this study, the investigators will examine the mechanisms by which this drug affects glucose metabolism and which cells are affected. Findings emanating from this project will help establish whether HCQ may be a viable treatment for disorders of glucose metabolism.

Conditions

Interventions

DRUG

Hydroxychloroquine

Hydroxychloroquine sulfate 400mg/d PO for 13±1 weeks

OTHER

Placebo

Placebo PO for 13±1 weeks

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Frederico Toledo, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02124681 on ClinicalTrials.gov